Department of Medicine, University of Toronto, Toronto, ON, Canada.
J Cutan Med Surg. 2013 May-Jun;17(3):173-9. doi: 10.2310/7750.2012.12050.
A new treatment for actinic keratoses, ingenol mebutate, was recently approved by the US Food and Drug Administration.
To review the mechanisms of action, efficacy and safety data, and practical recommendations for ingenol mebutate.
The PubMed and clinicaltrials.gov databases were searched in March/April 2012 using the terms PEP005, ingenol mebutate, and ingenol 3-angelate. The abstracts from the Annual Scientific Meeting of the Australian College of Dermatologists (2009-2011) and the Annual Meeting of the American Academy of Dermatology (2009-2012) were also searched.
Due to its multiple mechanisms of action, ingenol mebutate treatment resulted in short- and long-term efficacy similar to other topical treatments for actinic keratoses in a shorter period of 2 or 3 days. This short therapy would reduce the duration of adverse events. Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate.
Ingenol mebutate is a convenient, safe, and effective intervention for precancerous and cancerous skin conditions.
一种新型的光化性角化病治疗药物， ingenol mebutate（咪喹莫特），最近获得了美国食品药品监督管理局的批准。
综述 ingenol mebutate 的作用机制、疗效和安全性数据，以及其实际应用的建议。
我们于 2012 年 3-4 月，通过检索 PubMed 和 clinicaltrials.gov 数据库，使用了 PEP005、ingenol mebutate 和 ingenol 3-angelate 等关键词进行搜索。此外，还对澳大利亚皮肤病学会年会（2009-2011 年）和美国皮肤病学会年会（2009-2012 年）的摘要进行了搜索。
由于 ingenol mebutate 的多种作用机制，其治疗效果在短期和长期与其他光化性角化病的外用治疗相似，在短短 2-3 天内即可起效。这种短期治疗将减少不良反应的持续时间。非黑素瘤皮肤癌的上市前试验也显示 ingenol mebutate 有很好的疗效。
ingenol mebutate 是一种方便、安全、有效的治疗癌前和癌性皮肤疾病的方法。
